Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-06-13
2006-06-13
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S192100, C424S277100, C435S372000, C435S375000, C530S350000
Reexamination Certificate
active
07060279
ABSTRACT:
Disclosed are immunostimulatory fusion proteins and methods for generating protective DC-induced, T cell-mediated immune responses in vitro and in vivo. The immunostimulatory fusion proteins comprise a polypeptide antigen component and an immunostimulatory component derived from the intracellular domain of the HER-2 protein. Also disclosed are immunostimulatory compositions comprising dendritic cells pulsed with such an immunostimulatory fusion protein and methods for immunotherapy using the compositions.
REFERENCES:
patent: 4399216 (1983-08-01), Axel et al.
patent: 5846538 (1998-12-01), Cheever et al.
patent: 6080409 (2000-06-01), Laus et al.
patent: 6406681 (2002-06-01), Adjei et al.
patent: 6544518 (2003-04-01), Friede et al.
Tuzi NL, et al. Biochem Soc Trans. Oct. 1988;16(5):675-7.
Feinmesser RL, et al. Oncogene. Jun. 20, 1996; 12 (12): 2725-30.
van Lieshout EM, et al. Jpn J Cancer Res. Jan. 1999; 90 (1): 81-5.
Schechtman D, et al. Parasite Immunol. Apr. 2001; 23 (4): 213-7.
Wada H, et al. Proc Natl Acad Sci USA. Nov. 11, 1997; 94 (23): 12557-61.
Shimizu K, et al. Cancer Res. Mar. 15, 2001; 61 (6): 2618-24.
Wadhwa M, et al. Clin Cancer Res. Jun. 1999; 5 (6): 1353-61.
Fendly BM, et al. J Biol Response Mod. Oct. 1990; 9 (5): 449-55.
Burke CL, et al. Oncogene. 1997; 14: 687-96.
Inaba K, et al. J Exp Med. Aug. 1, 1990; 172 (2): 631-40.
Mitchell DA, et al. Eur J Immunol. Jun. 1998; 28 (6): 1923-33.
Sorkin A, et al. Oncogene. Nov. 1993; 8 (11): 3021-8.
Timmerman JM, et al. J Immunol. May 1, 2000; 164 (9): 4797-803.
Foy TM, et al. Semin Oncol. Jun. 2002; 29 (3 Suppl 11): 53-61.
Foy TM, et al. Vaccine. Mar. 21, 2001; 19 (17-19): 2598-606.
Disis ML, et al. Adv Cancer Res. 1997; 71: 343-71.
Vidovic D, et al. Int J Cancer. 2002; 102: 660-4.
PUBMED ID No.: 8206103 (abstract): Pucetti P, et al. Eur J Immunol. Jun. 1994; 24 (6): 1446-52.
PUBMED ID No.: 10738185 (abstract): Rieser C, et al. Urol Int. 1999; 63 (3): 151-9.
Toes RE, et al. J Immunol. May 1, 1998; 160 (9): 4449-56.
Ossevoort MA, et al. J Immunother Emphasis Tumor Immunol. Aug. 1995; 18 (2): 86-94.
Toes REM, et al. Proc Natl Acad Sci USA. Jul. 1996; 93: 7855-60.
Steinman RM. Ann Rev Immunol. 1991; 9: 271-96.
Vidovic et al. Int J Cancer. 2002; 102: 660-4.
Abbas, A.K., et al, W.B. Saunders Co., 116-123, 130-134, 394-405, (1997).
Adnane, J., et al, Oncogene, 4: 1389-1395, (1989).
Akiyama, T., et al, Science, 232: 1644-1646, (1986).
Bakker, A., et al., The Journal of Experimental Medicine, 179: 1005-1009, (1994).
Beckmann, M., et al., Eur. J. Cancer, 28: 322-326, (1992).
Chen, CH., et al, J Biomed Sci., 5: 231-252, (1998).
Coulie, P., et al., J. Exp. Med., 180: 35-42, (1994).
Coussens, L., et al., Science, 230: 1132-1139, (1985).
Cresswell, P., Annu. Rev. Immunol., 12: 259-293, (1994).
Czerniecki, B., et al., J. Immunol. 159: 3823-3837, (1997).
Di Fiore, P., et al., Science, 237: 178-182, (1987).
Engelhard, E., et al., Proc. Nat. Acad. Sci., 91: 3224-3227, (1994).
Germain, R., Ann. NY Acad. Sci., 754: 114-125, (1995).
Gotch, F., et al., Nature, 326: 881-882, (1987).
Greenberg, P., Adv. Immunol., 49: 281-355, (1991).
Heemels M., et al., Annu. Rev. Biochem., 64: 463-491, (1995).
Hudziak, R., et al., Proc. Natl. Acad. Sci. USA, 84: 7159-7163, (1987).
Jameson, S., et al., J. Exp. Med., 177: 1541-1550, (1993).
Kapitanovic, S., et al., Gastroenterology, 112: 1103-1113, (1997).
Kawakami, Y., et al., Proc. Natl. Acad. Sci., 91:3515-3519, (1994).
Keown, W., et al., Methods in Enzymology, 185: 527-537, (1990).
Kruisbeek, M., in Coligan et al. (eds.) Current Protocols in Immunology, Wiley, New York, NY, (1997) 3.14.1-3.14.11.
Muller, W., et al., Cell, 54: 105-115, (1988).
Paik, S.M., et al., Proc. Am. Assoc. Cancer Res., 32:291, (1991).
Pietras, R., et al., Oncogene, 10: 2435-2446, (1995).
Ridge, J., et al., Nature, 393: 474-478, (1998).
Robinson, H., et al., The American Academy for Microbiology, “The Scientific Future of DNA for Immunization” 1-31 (Colloquium Report), (1997).
Saffari, B., et al., Cancer Research, 55: 5693-5698, (1995).
Schirmbeck, R., et al., Eur. J. Immunol., 23: 1528-1534, (1993).
Slamon, D., et al., Science, 235: 177-182, (1987).
Slamon, D., et al., Science, 244: 707-712, (1989).
Tanaka, Y., et al., J. Immunol., 147:, 3646-3652, (1991).
Tsai, C.M.; et al., J. Natl. Cancer Inst., 85: 897-901, (1993).
Tsai, C.M., et al., J. Natl. Cancer Inst., 87: 682-684, (1995).
Wang, M., et al., J. Immunol., 154: 4685-4692, (1995).
Wright, C., et al., Br. J. Cancer, 65:118-121, (1992).
Yu, D., et al., Oncogene, 6: 1991-1996, (1991).
Yu, D. et al., Cancer Res., 53: 891-898, (1993).
Zeillinger, R., et al., Oncogene, 4: 109-114, (1989).
Zhau, H., et al., Prostate, 28: 73-83, (1996).
Graddis Thomas
Laus Reiner
Vidovic Damir
Dendreon Corporation
Helms Larry R.
Perkins Coie LLP
Rawlings Stephen L.
LandOfFree
Compositions and methods for dendritic cell-based immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for dendritic cell-based immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for dendritic cell-based immunotherapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3680562